Equities

Zhejiang Hisun Pharmaceutical Co Ltd

600267:SHH

Zhejiang Hisun Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)8.35
  • Today's Change-0.33 / -3.80%
  • Shares traded17.41m
  • 1 Year change-18.70%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zhejiang Hisun Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of specialty bulk pharmaceutical chemicals and preparation products. The Company's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infection drugs, endocrine control drugs, anthelmintic, as well as animal remedies, among others. The Company is also engaged in the sales of drugs manufactured by other companies. The Company distributes its products in domestic markets and to overseas markets.

  • Revenue in CNY (TTM)9.55bn
  • Net income in CNY-34.96m
  • Incorporated1998
  • Employees8.06k
  • Location
    Zhejiang Hisun Pharmaceutical Co LtdNo. 46, Waisha Road, Jiaojiang DistrictTAIZHOU 318000ChinaCHN
  • Phone+86 57 185278141
  • Fax+86 57 688827887
  • Websitehttp://www.hisunpharm.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
North China Pharmaceutical Co Ltd9.71bn79.38m9.63bn10.16k120.571.79--0.99170.04650.04655.683.130.44922.674.34955,385.000.6731-0.29781.54-0.704229.7935.731.50-0.59850.56091.640.6482---3.621.89100.71-49.624.22-19.73
GuangYuYuan Chinese Herbal Medicn Co Ltd1.24bn136.56m9.64bn1.81k70.586.15--7.770.2790.2792.533.200.50110.56472.60684,557.406.04-2.108.71-3.1672.2169.7412.05-6.000.987321.000.0267--13.56-4.53136.03-24.78-58.35--
Harbin Pharmaceutical Group Co., Ltd.16.22bn613.05m9.72bn9.85k15.961.87--0.59940.24180.24186.382.071.156.293.471,646,115.004.780.741412.561.8927.6023.874.150.72941.1136.800.36330.0011.937.41-14.882.69-5.38--
Youcare Pharmaceutical Group Co Ltd4.23bn242.25m9.86bn3.18k40.732.69--2.330.53820.53829.398.140.72212.335.371,330,727.004.117.116.0411.6558.6264.145.708.071.52105.130.193960.95-7.611.05-44.84-7.1623.40--
Nanjing Vazyme Biotech Co Ltd1.40bn23.59m10.01bn2.70k406.792.51--7.140.06150.06153.849.970.26441.063.57519,483.100.412213.160.523715.9270.2170.501.5623.924.17--0.143632.20-63.9749.74-111.94--48.61--
Chongqing Genrix Biophrmctcl Co Ltd13.56m-779.42m10.11bn547.00--4.30--745.51-2.13-2.130.0376.420.00390.10091.3724,790.27-22.22---23.06--55.87---5,747.82--18.62--0.2454--154.92---39.03------
Zhejiang Hisun Pharmaceutical Co., Ltd.9.55bn-34.96m10.48bn8.06k--1.27--1.10-0.0412-0.04128.206.830.5553.234.281,184,162.00-0.34671.95-0.56633.7739.0840.58-0.62483.430.6491--0.369626.07-13.820.3618-119.05---31.58--
Mayinglong Pharmaceutical Group Co Ltd3.48bn482.37m10.99bn2.88k22.792.75--3.161.121.128.089.280.68726.428.531,208,299.009.7410.8211.6413.4744.8441.1814.1714.084.40--0.093633.04-11.207.38-7.4620.2658.3321.67
Changchun BCHT Biotechnology Co1.61bn414.29m11.07bn1.24k26.742.64--6.891.001.003.8810.150.31811.001.061,295,333.008.209.9510.2312.8187.5586.6325.7724.031.85--0.014710.5570.3012.36175.9831.3721.04--
Heilongjiang ZBD Pharmaceutical Co Ltd2.58bn114.60m11.23bn2.55k99.861.45--4.350.11940.11942.748.240.21181.480.76451,014,704.000.88223.481.174.7834.5238.934.1710.082.23--0.288827.18-25.502.45155.000.4417-25.684.05
Cansino Biologics Inc748.53m-720.11m11.30bn1.49k--3.28--15.10-2.92-2.923.0320.460.08510.63411.12501,023.80-8.41-4.27-11.09-5.5967.7141.73-98.82-27.602.27-8.750.2934---65.49163.48-63.04--30.60--
Data as of Nov 22 2024. Currency figures normalised to Zhejiang Hisun Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

2.69%Per cent of shares held by top holders
HolderShares% Held
GF Fund Management Co., Ltd.as of 30 Jun 202412.02m1.10%
Yinhua Fund Management Co., Ltd.as of 30 Jun 20246.96m0.64%
The Vanguard Group, Inc.as of 30 Sep 20242.79m0.26%
China Asset Management Co., Ltd.as of 30 Jun 20242.49m0.23%
Dimensional Fund Advisors LPas of 07 Nov 20241.80m0.17%
Da Cheng Fund Management Co., Ltd.as of 30 Jun 20241.13m0.10%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20241.03m0.09%
Wanjia Asset Management Co., Ltd.as of 30 Jun 2024809.20k0.07%
Western Asset Management Co. Pty Ltd.as of 30 Jun 2024201.60k0.02%
China Southern Asset Management Co., Ltd.as of 30 Jun 2024186.60k0.02%
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.